Molecular Hematology
Description
Molecular Hematology is a comprehensive resource for hematologists to increase their understanding of the molecular basis of various blood diseases, their pathogeneses, and current and emerging molecular research and therapies. The impact of molecular research on the field of hematology is significant--molecular techniques are continuing to play a central role in in the diagnosis and treatment of blood diseases. Molecular characterization of genes and proteins has increased our comprehension of the causes of hematological diseases and led to the development of new drug therapies and recombinant proteins.
Now in its fourth edition, Molecular Hematology has been thoroughly revised and updated to reflect current advances in molecular research. Chapters introduce and summarize specific disorders, such as hemophilia, anemia, and multiple myeloma, and illustrate the impact of molecular research on their diagnoses and treatments. Contributions written by respected clinicians and researchers offer accessible coverage of topics including lymphoma genetics, molecular coagulation and thrombophilia, platelet disorders, pharmacogenomics, and many others.
* Demonstrates the clinical relevance of molecular biology in hematology
* Provides overviews of recent advances in cancer-cell biology, with an emphasis on leukemia and lymphoma
* Offers new and updated chapters written by an international team of experts in the field
* Presents new full-color charts, graphs, and illustrations
* Includes access to a Wiley Companion Digital Edition providing search across the book, downloadable illustrations and notation tools
Molecular Hematology is an essential volume for both trainee and practicing hematologists and oncologists, molecular biologists, and research scientists working in the field of hematology.
More details
Other editions
Additional editions
Persons
DREW PROVAN, MD, FRCP, FRCPath, is Emeritus Reader in Autoimmune Haematology, Department of Haematology, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, UK.
JOHN G. GRIBBEN, MD, DSc, FRCP, FRCPath, FMedSci, is The Gordon Hamilton Fairley Professor of Medical Oncology, Barts Cancer Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, UK.
Content
Contributors ix
Preface to the fourth edition xiii
Further reading xv
Acknowledgments xvi
1 Beginnings: the molecular pathology of hemoglobin 1
David Weatherall
2 Stem cells 21
David T. Scadden
3 The genetics of acute myeloid leukemias 37
Amy M. Trottier & Carolyn J. Owen
4 Molecular diagnostics and risk assessment in myeloid malignancies 49
Christian Scharenberg & Torsten Haferlach
5 Molecular basis of acute lymphoblastic leukemia 59
Bela Patel & Fiona Fernando
6 Chronic myeloid leukemia 71
Hagop Kantarjian, Jorge Cortes, Elias Jabbour & Susan O'Brien
7 Myeloproliferative neoplasms 87
Jyoti Nangalia, Anthony J. Bench, Anthony R. Green & Anna L. Godfrey
8 Lymphoma genetics 101
Jennifer L. Crombie, Anthony Letai & John G. Gribben
9 The molecular biology of chronic lymphocytic leukemia 111
John G. Gribben
10 The molecular biology of multiple myeloma 121
Wee Joo Chng & P. Leif Bergsagel
11 The molecular basis of bone marrow failure syndromes and red cell enzymopathies 131
Deena Iskander, Lucio Luzzatto & Anastasios Karadimitris
12 Anemia of chronic disease 155
Tomas Ganz
13 The molecular basis of iron metabolism 161
Nancy C. Andrews & Tomas Ganz
14 Hemoglobinopathies due to structural mutations 173
D. Mark Layton & Steven Okoli
15 Molecular pathogenesis of malaria 193
David J. Roberts, Arnab Pain & Chetan E. Chitnis
16 Molecular coagulation and thrombophilia 207
Björn Dahlbäck & Andreas Hillarp
17 The molecular basis of hemophilia 221
Daniel P. Hart & Paul L.F. Giangrande
18 The molecular basis of von Willebrand disease 235
Luciano Baronciani
19 Platelet disorders 251
Kenneth J. Clemetson
20 The molecular basis of blood cell alloantigens 267
Cristina Navarrete, Louise Tilley, Winnie Chong & Colin J. Brown
21 Functions of blood group antigens 285
Jonathan S. Stamler & Marilyn J. Telen
22 Autoimmune hematological disorders 297
Drew Provan & John W. Semple
23 Molecular therapeutics in hematology: gene therapy 319
William M. McKillop & Jeffrey A. Medin
24 Pharmacogenomics 339
Leo Kager & William E. Evans
25 History and development of molecular biology 353
Paul Moss
26 Cancer stem cells 363
Sara Ali & Dominique Bonnet
27 Molecular basis of transplantation 373
Francesco Dazzi & Antonio Galleu
Index 389
Contributors
- Sara Ali MD
- Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, UK
- Nancy C. Andrews MD, PhD
- Duke University School of Medicine, Durham, NC, USA
- Luciano Baronciani PhD
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy
- Anthony J. Bench MA, PhD
- Laboratory Medicine, NHS Lothian, Edinburgh, UK
- P. Leif Bergsagel MD
- Division of Hematology-Oncology, Comprehensive Cancer Center, Mayo Clinic Arizona, Scottsdale, AZ, USA
- Dominique Bonnet PhD
- Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, UK
- Colin J. Brown PhD, FRCPath
- Histocompatibility and Immunogenetics Laboratory, NHS Blood and Transplant; Faculty of Life Sciences & Medicine, King's College London, London, UK
- Chetan E. Chitnis MSc, MA, PhD
- Malaria Group, Pasteur Institute, Paris, France
- Wee Joo Chng MB ChB, MRCP, FRCPath
- National University Cancer Institute, National University Health System of Singapore; University of Singapore, National University Hospital, Singapore
- Winnie Chong PhD
- Histocompatibility and Immunogenetics Service Development Laboratory, NHS Blood and Transplant, London, UK
- Kenneth J. Clemetson PhD, ScD, CChem, FRSC
- Department of Haematology, Inselspital, University of Berne, Berne, Switzerland
- Jorge Cortes MD
- Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Jennifer L. Crombie MD
- Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
- Björn Dahlbäck MD, PhD
- Department of Translational Medicine, Section of Clinical Chemistry, Lund University, University Hospital, Malmö, Sweden
- Francesco Dazzi MD, PhD
- School of Cancer & Pharmaceutical Sciences, King's College London; King's Health Partners Cancer Research UK Centre, London, UK
- William E. Evans PharmD
- St Jude Children's Research Hospital, Memphis, TN, USA
- Fiona Fernando MD
- Centre of Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK
- Antonio Galleu MD, PhD
- School of Cancer & Pharmaceutical Sciences, King's College London; King's Health Partners Cancer Research UK Centre, London, UK
- Tomas Ganz PhD, MD
- Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
- Paul L.F. Giangrande MD, FRCP, FRCPath, FRCPCH
- Formerly of Oxford Haemophilia and Thrombosis Centre, Churchill Hospital, Oxford, UK
- Anna L. Godfrey PhD, MRCP, FRCPath
- Department of Haematology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
- Anthony R. Green PhD, FRCP, FRCPath, FMedSci
- Department of Haematology, Cambridge Institute for Medical Research; Wellcome Medical Research Council Stem Cell Institute, Cambridge, UK
- John G. Gribben MD, DSc, FRCP, FRCPath, FMedSci
- Barts Cancer Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK
- Torsten Haferlach MD
- MLL Munich Leukemia Laboratory, Munich, Germany
- Daniel P. Hart FRCP, FRCPath, PhD
- The Royal London Hospital Haemophilia Centre, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK
- Andreas Hillarp PhD
- Department of Clinical Chemistry and Transfusion Medicine, Halland County Hospital, Halmstad, Sweden
- Deena Iskander MD, PhD, MRCP
- Centre for Haematology, Imperial College London, Hammersmith Hospital, London, UK
- Elias Jabbour MD
- Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Leo Kager MD
- Department of Pediatrics, St. Anna Children's Hospital, Medical University Vienna, Austria
- Hagop Kantarjian MD
- Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Anastasios Karadimitris PhD, MRCP, FRCPath
- Department of Haematology and Blood Transfusion, Muhimbili University College of Health Sciences, Dar-es-Salaam, Tanzania
- D. Mark Layton MB BS, FRCP, FRCPCH
- Center for Hematology, Imperial College London, London, UK
- Anthony Letai MD, PhD
- Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
- Lucio Luzzatto MD
- Department of Haematology and Blood Transfusion, Muhimbili University College of Health Sciences, Dar-es-Salaam, Tanzania
- William M. McKillop PhD
- Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI, USA
- Jeffrey A. Medin PhD
- Departments of Pediatrics and Biochemistry, Medical College of Wisconsin, Milwaukee, WI, USA
- Paul Moss MD, PhD
- School of Cancer Sciences, University of Birmingham, Birmingham, UK
- Jyoti Nangalia PhD, MRCP, FRCPath
- Welcome Sanger Institute, Hinxton; Department of Haematology, University of Cambridge; Wellcome-Medical Research Council Cambridge Stem Cell Institute, Cambridge, UK
- Cristina Navarrete PhD, FRCPath
- Histocompatibility and Immunogenetics Service Development Department, NHS Blood and Transplant; Department of Immunology and Molecular Pathology, University College London, London, UK
- Susan O'Brien MD
- Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Steven Okoli MBChB, FRCP, FRCPath
- Center for Hematology, Imperial College London, London, UK
- Carolyn J. Owen MD, MDres(UK), FRCPC
- Division of Hematology and Hematological Malignancies, University of Calgary, Foothills Medical Centre, Calgary, Canada
- Arnab Pain PhD
- Biological and Environmental Sciences and Engineering (BESE) Division, King Abdullah University of Science and Technology, Jeddah, Saudi Arabia; Nuffield Division of Clinical Laboratory Sciences (NDCLS), The John Radcliffe Hospital, University of Oxford, Headington, Oxford, UK
- Bela Patel MD, FRCPath, MD(res)
- Centre of Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK
- Drew Provan MD, FRCP, FRCPath
- Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK
- David J. Roberts DPhil, MRCP, FRCPath
- National Health Service Blood and Transplant (Oxford), The John Radcliffe Hospital, Oxford, UK
- David T. Scadden MD
- Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Harvard University; Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA, USA
- Christian Scharenberg MD, PhD
- Department of Hematology, Skaraborgs Hospital, Skövde; Department of Cell and Molecular Biology, Karolinska Institute, Stockholm, Sweden
- John W. Semple PhD
- Division of Hematology and Transfusion Medicine, Lund University, Lund, Sweden
- Jonathan S. Stamler MD
- Harrington Discovery Institute and Institute of Transformative Molecular Medicine, University Hospitals Cleveland Medical Center and Case Western Reserve University, Cleveland, OH, USA
- Marilyn J. Telen MD
- Department of Medicine, Division of Hematology, Duke University Medical Center, Durham, NC, USA
- Louise Tilley PhD
- International Blood Group Reference Laboratory, NHS Blood and Transplant, Bristol, UK
- Amy M. Trottier MSc, MD, FRCPC
- Division of Hematology and Hematological Malignancies, University of Calgary, Foothills Medical Centre, Calgary, Canada
- David Weatherall MD, FRCP, FRS
- Formerly of Weatherall Institute of Molecular Medicine, The John...
